)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Kymera Therapeutics (KYMR) investor relations material
Kymera Therapeutics Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Result summary8 Dec, 2025
Strategic Overview and Rationale
KT-621 is a first-in-class oral STAT6 degrader targeting Type 2 inflammation in diseases such as atopic dermatitis (AD), asthma, and allergic rhinitis, aiming to provide a biologics-like effect in an oral formulation.
The approach leverages targeted protein degradation to address previously undruggable or hard-to-drug targets, focusing on unmet needs in immunology.
Oral degraders offer continuous pathway suppression, potentially matching or exceeding biologics in efficacy and safety, while improving convenience and access.
The market opportunity is significant, as only a small fraction of eligible patients currently receive advanced systemic therapies, mostly biologics.
KT-621 is positioned to expand access to millions of patients not currently treated with advanced therapies.
Study Design and Patient Population
Open-label, single-arm Phase 1b trial enrolled 22 moderate to severe AD patients across two dose levels (100 mg and 200 mg) for 28 days, followed by 14-day follow-up.
Patients had documented topical corticosteroid failure; prior biologic use allowed after washout.
Dose groups were balanced for gender, age, race, and disease severity; 46% had comorbid asthma or allergic rhinitis, and 23% had prior biologic treatment.
The study included a diverse population, with over half Black or African American and nearly a quarter Hispanic or Latino.
Baseline characteristics were well balanced across cohorts, with high disease burden and frequent comorbid asthma or allergic rhinitis.
Pharmacodynamics and Biomarker Results
KT-621 achieved deep STAT6 degradation (98% in blood, 94% in skin) at both dose levels, maintained through dosing, with strong translation from healthy volunteers to patients.
Robust reductions in Type 2 inflammation biomarkers: TARC (up to 74%), Eotaxin-3 (up to 73%), IgE (up to 14%), IL-31 (up to 56%), and FeNO (up to 56%).
First demonstration of IL-31 and FeNO reduction in AD patients with IL-4/13 pathway blockade.
Transcriptomic analysis of skin biopsies showed significant downregulation of Type 2 and AD-relevant genes, mirroring dupilumab effects.
Conjunctivitis rates vs. current biologics?
Phase 3 dose selection strategy?
How will oral dosing impact AD treatment paradigm?
Absence of Dupi-like AEs: implications?
Oral STAT6: market expansion potential?
FeNO data: impact on asthma strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kymera Therapeutics earnings date
Q4 202526 Feb, 2026
Next Kymera Therapeutics earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapies. The company’s proprietary platform aims to design small-molecule drugs that selectively degrade disease-causing proteins, offering a novel approach to treating conditions that have been difficult to address with traditional therapies. Kymera Therapeutics is engaged in research and development across various therapeutic areas, including oncology, immunology, and inflammation. The company is headquartered in Watertown, United States, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage